Furosemide Tablet
FDA Recall NDC 64980-562

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Furosemide (NDC 64980-562). A significant event, classified as Class II, was initiated on Jan 10, 2026 by Rising Pharma Holdings, Inc.. The reported reason for this action was: "Presence of Foreign Substance"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

January 2026 Class II Recall: Presence of Foreign Substance

Recall Number
Class II Ongoing
Reason for Recall
Presence of Foreign Substance
Initiated
Jan 10, 2026
Reported
Jan 28, 2026
Quantity
4212 bottles

Recall Profile & Regulatory Data

Event ID
98289
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Graviti Pharmaceuticals Private Limited
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
U.S. Nationwide
Product Description
Furosemide Tablets, USP 40 mg, 1,000 Tablets, Rx Only, Manufactured for: Rising Pharmaceuticals Inc., East Brunswick, NJ 08816, Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, India, NDC 64980-563-10.
Batch or Lot Expiration Information
Lot# FUB125042G; Exp. 05/13/2027
Affected Packages Involved in this Recall
64980-562-01Product
64980-562-10Product
64980-563-01Product
64980-563-10Product
64980-564-01Product
64980-564-50Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.